Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15717246 | 0.87 | MCHR1 (0.40) | NTRK1MLYCD | |
| SCHEMBL15717119 | 0.82 | MLYCD (0.39) | NTRK1MLYCD | |
| SCHEMBL15717420 | 0.81 | NTRK1 (0.37) | NTRK1 | |
| SCHEMBL15718134 | 0.79 | TACR1 (0.46) | MLYCD | |
| SCHEMBL15739586 | 0.79 | BRD4 (0.38) | NTRK1 | |
| SCHEMBL15717870 | 0.78 | POLB (0.38) | — | |
| SCHEMBL15717681 | 0.78 | NR3C1 (0.44) | NTRK1 | |
| SCHEMBL15717853 | 0.78 | KMT2A (0.38) | NTRK1 | |
| SCHEMBL15718266 | 0.77 | MCHR1 (0.38) | NTRK1 | |
| SCHEMBL15717796 | 0.77 | CYP11B2 (0.41) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2019-01-31 | — | — | US | claimed |
| EP-3405468-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | Novartis AG (CH) | 2018-11-28 | — | — | EP | claimed |
| EP-2325385-B1 | COMPOSITION FOR THE IMPREGNATION OF FIBERS, FABRICS AND NETTINGS IMPARTING A PROTECTIVE ACTIVITY AGAINST PESTS | BASF SE (DE) | 2017-10-04 | — | — | EP | claimed |
| EP-2925757-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | claimed |
| WO-2017125898-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2017-07-27 | — | — | WO | claimed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | claimed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | claimed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | claimed |
| EP-2925757-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2015-10-07 | — | — | EP | claimed |
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-01-08 | — | — | US | claimed |
| US-8871754-B2 | Compounds and compositions for the treatment of parasitic diseases | IRM LLC (BM) | 2014-10-28 | — | — | US | claimed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | claimed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | claimed |
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2019-01-31 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078214-A1 | AZETIDINE BENZIMIDAZOLES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | NTRK1 4885/4885GSK3A 86/4885GSK3B 63/4885 |
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | NTRK1 4885/4885GSK3A 86/4885GSK3B 63/4885 |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | NTRK1 4885/4885GSK3A 86/4885GSK3B 63/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | NTRK1 4885/4885GSK3A 86/4885GSK3B 63/4885 |
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | PI4KA, PI4K2A, PIP4K2A | NTRK1 4728/4885GSK3A 104/4885GSK3B 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.